-
Something wrong with this record ?
Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases
P. Kušnierová, D. Zeman, P. Hradílek, O. Zapletalová, D. Stejskal,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Biomarkers cerebrospinal fluid MeSH
- Demyelinating Diseases cerebrospinal fluid diagnosis MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Prognosis MeSH
- Chitinase-3-Like Protein 1 cerebrospinal fluid MeSH
- Multiple Sclerosis cerebrospinal fluid diagnosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVES: Chitinase 3-like 1 (CHI3L1) is an extracellular monomeric single-chain glycoprotein expressed by many types of cells. Its elevated levels were found in cerebrospinal fluid in central nervous system (CNS) inflammatory diseases patients. The aim of the study was 1) to validate the reference interval of cerebrospinal fluid (CSF) CHI3L1 in a control group; 2) to measure the CHI3L1 concentration in different diagnosis groups .including multiple sclerosis (MS); and 3) to correlate those values with other biomarkers of axonal damage or neuroinflammation in different grous. METHODS: The study included 132 CSF samples sent to the Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava. Concentrations of CHI3L1, CXCL13 chemokine, neurofilament light chains, and phosphorylated neurofilament heavy chains were determined by enzyme-linked immunosorbent assays. IgG oligoclonal bands were detected by isoelectric focusing in agarose gels followed by immunofixation. IgM and FLC oligoclonal bands were analyzed by IEF followed by affinity immunoblotting. The group consisted of 42 patients with multiple sclerosis, 14 with clinically isolated syndrome, 11 with other central nervous system inflammatory diseases, 46 with non-inflammatory diseases of the central nervous system, 4 with inflammatory diseases of the peripheral nervous system, and 15 controls. RESULTS: The estimated reference values of CHI3L1 were 28.6-182.5 μg.L-1. Statistically significant differences of CSF CHI3L1 concentrations were found among diagnosis groups (p < 0.0001), after age adjustment (p = 0.002). There was a statistically significant relationship between CHI3L1 and NFL in the MS group (rs = 0.460; P = 0.002), and between CHI3L1 and pNFH in the MS group (rs = 0.691; P < 0.001). No statistically significant difference was found in the categorical comparison of CHI3L1 in the MS group and other diagnostic groups as well as when using the Mann-Whitney U test for CHI3L1 with additional parameters with and without oligoclonal bands present. CONCLUSIONS: CSF CHI3L1 values differ depending on diagnosis and correlate significantly with concentrations of the axonal damage markers CSF neurofilament light chains, and CSF phosphorylated neurofilament heavy chains, but not with CSF concentrations of the inflammatory marker CXCL13. Thus, CSF CHI3L1 could be another promising prognostic, albeit probably etiologically nonspecific, biomarker of MS.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025003
- 003
- CZ-PrNML
- 005
- 20201222155005.0
- 007
- ta
- 008
- 201125s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0233519 $2 doi
- 035 __
- $a (PubMed)32437412
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kušnierová, Pavlína $u Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
- 245 10
- $a Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases / $c P. Kušnierová, D. Zeman, P. Hradílek, O. Zapletalová, D. Stejskal,
- 520 9_
- $a OBJECTIVES: Chitinase 3-like 1 (CHI3L1) is an extracellular monomeric single-chain glycoprotein expressed by many types of cells. Its elevated levels were found in cerebrospinal fluid in central nervous system (CNS) inflammatory diseases patients. The aim of the study was 1) to validate the reference interval of cerebrospinal fluid (CSF) CHI3L1 in a control group; 2) to measure the CHI3L1 concentration in different diagnosis groups .including multiple sclerosis (MS); and 3) to correlate those values with other biomarkers of axonal damage or neuroinflammation in different grous. METHODS: The study included 132 CSF samples sent to the Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava. Concentrations of CHI3L1, CXCL13 chemokine, neurofilament light chains, and phosphorylated neurofilament heavy chains were determined by enzyme-linked immunosorbent assays. IgG oligoclonal bands were detected by isoelectric focusing in agarose gels followed by immunofixation. IgM and FLC oligoclonal bands were analyzed by IEF followed by affinity immunoblotting. The group consisted of 42 patients with multiple sclerosis, 14 with clinically isolated syndrome, 11 with other central nervous system inflammatory diseases, 46 with non-inflammatory diseases of the central nervous system, 4 with inflammatory diseases of the peripheral nervous system, and 15 controls. RESULTS: The estimated reference values of CHI3L1 were 28.6-182.5 μg.L-1. Statistically significant differences of CSF CHI3L1 concentrations were found among diagnosis groups (p < 0.0001), after age adjustment (p = 0.002). There was a statistically significant relationship between CHI3L1 and NFL in the MS group (rs = 0.460; P = 0.002), and between CHI3L1 and pNFH in the MS group (rs = 0.691; P < 0.001). No statistically significant difference was found in the categorical comparison of CHI3L1 in the MS group and other diagnostic groups as well as when using the Mann-Whitney U test for CHI3L1 with additional parameters with and without oligoclonal bands present. CONCLUSIONS: CSF CHI3L1 values differ depending on diagnosis and correlate significantly with concentrations of the axonal damage markers CSF neurofilament light chains, and CSF phosphorylated neurofilament heavy chains, but not with CSF concentrations of the inflammatory marker CXCL13. Thus, CSF CHI3L1 could be another promising prognostic, albeit probably etiologically nonspecific, biomarker of MS.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a protein CHI3L1 $x mozkomíšní mok $7 D000071451
- 650 _2
- $a demyelinizační nemoci $x mozkomíšní mok $x diagnóza $7 D003711
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a roztroušená skleróza $x mozkomíšní mok $x diagnóza $7 D009103
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zeman, David $u Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic. Clinic of Neurology, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Hradílek, Pavel $u Clinic of Neurology, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Zapletalová, Olga $u Clinic of Neurology, University Hospital Ostrava, Ostrava, Czech Republic.
- 700 1_
- $a Stejskal, David $u Department of Clinical Biochemistry, Institute of Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 15, č. 5 (2020), s. e0233519
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32437412 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222155001 $b ABA008
- 999 __
- $a ok $b bmc $g 1599148 $s 1115689
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 15 $c 5 $d e0233519 $e 20200521 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20201125